Skip to main content
Erschienen in: Pediatric Cardiology 5/2005

01.10.2005

Nitric Oxide in the Evaluation of Congenital Heart Disease with Pulmonary Hypertension: Factors Related to Nitric Oxide Response

verfasst von: B.C. Cannon, T.F. Feltes, J. Kennard Fraley, R.G. Grifka, E.M. Riddle, J.P. Kovalchin

Erschienen in: Pediatric Cardiology | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Inhaled nitric oxide (NO) has been used in the preoperative evaluation of patients with congenital heart disease and pulmonary hypertension. The purpose of this study was to characterize responses in pulmonary vascular resistance (PVR) to oxygen and increasing doses of NO during cardiac catheterization and to determine if any related factors affect the response of the pulmonary vascular bed to NO. A prospective analysis of 42 patients (median age, 3.0 years) with congenital heart disease and pulmonary hypertension who underwent NO testing was performed. Systemic vascular resistance (SVR) and PVR were assessed in room air, 100% oxygen, and oxygen plus 20, 40, and 80 parts per million (ppm) NO. Changes in pulmonary artery pressure, PVR, and SVR were assessed. The response to NO was then correlated to individual patient’s age, gender, type of heart defect, the presence of trisomy 21, and baseline PVR/SVR. There was a greater decrease in PVR and PVR/SVR with 20 ppm NO than with oxygen alone. There was no additional decrease at 40 or 80 ppm NO. There was no correlation between age, gender, type of congenital heart disease, and baseline PVR/SVR ratio with the degree of response to NO. Patients with trisomy 21 had less of a response to NO (p = 0.017) than patients without trisomy 21. There is no difference in determining PVR response with doses of NO beyond 20 ppm during cardiac catheterization. Age, gender, and baseline PVR/SVR ratio are not associated with responsiveness to NO. Patients with trisomy 21 may be less responsive to NO.
Literatur
1.
Zurück zum Zitat Atz, AM, Adatia, I, Lock, JE, Wessel, DL 1999Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testingJ Am Coll Cardiol33813819PubMedCrossRef Atz, AM, Adatia, I, Lock, JE, Wessel, DL 1999Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testingJ Am Coll Cardiol33813819PubMedCrossRef
2.
Zurück zum Zitat Azeka, E, Costa Auler, JO, Kajita, L, et al. 2002Effects of low doses of inhaled nitric oxide combined with oxygen for the evaluation of pulmonary vascular reactivity in patients with pulmonary hypertensionPediatr Cardiol232026PubMedCrossRef Azeka, E, Costa Auler, JO, Kajita, L,  et al. 2002Effects of low doses of inhaled nitric oxide combined with oxygen for the evaluation of pulmonary vascular reactivity in patients with pulmonary hypertensionPediatr Cardiol232026PubMedCrossRef
3.
Zurück zum Zitat Balzer, DT, Kort, HW, Day, RW, et al. 2002Inhaled nitric oxide as a preoperative test (INOP test I)Circulation106I76-I-81 Balzer, DT, Kort, HW, Day, RW,  et al. 2002Inhaled nitric oxide as a preoperative test (INOP test I)Circulation106I76-I-81
4.
Zurück zum Zitat Beghetti, M, Habre, W, Friedli, B, Berner, M 1995Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac sugery in paediatric patientsBr Heart J736568PubMed Beghetti, M, Habre, W, Friedli, B, Berner, M 1995Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac sugery in paediatric patientsBr Heart J736568PubMed
5.
Zurück zum Zitat Chi, TL, Krovetz, LJ 1975The pulmonary vascular bed in children with Down syndromeJ Pediatr86533538 Chi, TL, Krovetz, LJ 1975The pulmonary vascular bed in children with Down syndromeJ Pediatr86533538
6.
Zurück zum Zitat Curran, RD, Mavroudis, , Backer, CL, et al. 1995Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertensionAnn Thorac Surg6017651771PubMedCrossRef Curran, RD, Mavroudis, , Backer, CL,  et al. 1995Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertensionAnn Thorac Surg6017651771PubMedCrossRef
7.
Zurück zum Zitat Day, RW, Lynch, JM, Shaddy, RE, Orsmond, GS 1995Pulmonary vasodilatory effects of 12 and 60 perts per million inhaled nitric oxide in children with ventricular septal defectAm J Cardiol75196198PubMedCrossRef Day, RW, Lynch, JM, Shaddy, RE, Orsmond, GS 1995Pulmonary vasodilatory effects of 12 and 60 perts per million inhaled nitric oxide in children with ventricular septal defectAm J Cardiol75196198PubMedCrossRef
8.
Zurück zum Zitat Firmer, NN, Etches, PC, Kamstra, B, et al. 1994Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose responseJ Pediatr124302308 Firmer, NN, Etches, PC, Kamstra, B,  et al. 1994Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose responseJ Pediatr124302308
9.
Zurück zum Zitat Miller, OI, Celermajer, DS, Deanfield, JE, Macrae, DJ 1994Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart diseaseJ Thorac Cardiovasc Surg108487494PubMed Miller, OI, Celermajer, DS, Deanfield, JE, Macrae, DJ 1994Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart diseaseJ Thorac Cardiovasc Surg108487494PubMed
10.
Zurück zum Zitat Roberts, JD JR, Lang, P, Bigatello, LM, Vlahakes, GJ, Zapol, WM 1993Inhaled nitric oxide in congenital heart diseaseCirculation87447453PubMed Roberts, JD JR, Lang, P, Bigatello, LM, Vlahakes, GJ, Zapol, WM 1993Inhaled nitric oxide in congenital heart diseaseCirculation87447453PubMed
11.
Zurück zum Zitat Wessel, DL 2001Current and future strategies in the treatment of childhood pulmonary hypertensionProg Pediatr Cardiol12289318CrossRef Wessel, DL 2001Current and future strategies in the treatment of childhood pulmonary hypertensionProg Pediatr Cardiol12289318CrossRef
Metadaten
Titel
Nitric Oxide in the Evaluation of Congenital Heart Disease with Pulmonary Hypertension: Factors Related to Nitric Oxide Response
verfasst von
B.C. Cannon
T.F. Feltes
J. Kennard Fraley
R.G. Grifka
E.M. Riddle
J.P. Kovalchin
Publikationsdatum
01.10.2005
Erschienen in
Pediatric Cardiology / Ausgabe 5/2005
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-004-0767-5

Weitere Artikel der Ausgabe 5/2005

Pediatric Cardiology 5/2005 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.